Iwai Shuji, Sakaguchi Hiroki, Fujii Hideki, Kobayashi Sawako, Morikawa Hiroyasu, Enomoto Masaru, Tamori Akihiro, Kawada Norifumi
Department of Hepatology, Osaka City University, Osaka, Japan.
Hepatogastroenterology. 2012 Mar-Apr;59(114):546-50. doi: 10.5754/hge11988.
BACKGROUND/AIMS: Radiofrequency ablation (RFA) with artificial pleural effusion and/or artificial ascites has recently been recognized as a useful device for the treatment of hepatocellular carcinoma (HCC). However, the indication of this technique is unclear and its therapeutic efficacy is undetermined.
We decided the precise indication for the use of artificial infusion. Artificial pleural effusion was indicated for tumors located on the dorsal side of the liver surface in the right lobe. Artificial ascites were indicated for (i) tumors located on the ventral side of the liver surface in the right lobe; (ii) tumors that could not be completely visualized but located near the liver surface in the right lobe; and (iii) tumors on the liver surface and adjacent to organs.
The total local recurrence rates at 1 and 2 years were 4% and 22%, respectively. The estimated survival rates of 32 naïve patients at 1 and 3 years were 90% and 78%, respectively. The local recurrence rates of a tumor size of <3 cm and >3 cm at 2 years were 22% and 17%, respectively.
RFA with artificial pleural effusion and/or ascites is effective for tumors located on the liver surface and in the hepatic dome.
背景/目的:带有人工胸腔积液和/或人工腹水的射频消融术(RFA)最近已被公认为是一种治疗肝细胞癌(HCC)的有用手段。然而,该技术的适应症尚不清楚,其治疗效果也未确定。
我们确定了人工输注的精确适应症。人工胸腔积液适用于位于右叶肝表面背侧的肿瘤。人工腹水适用于:(i)位于右叶肝表面腹侧的肿瘤;(ii)无法完全可视化但位于右叶肝表面附近的肿瘤;以及(iii)位于肝表面且与器官相邻的肿瘤。
1年和2年的总局部复发率分别为4%和22%。32例初治患者1年和3年的估计生存率分别为90%和78%。肿瘤大小<3 cm和>3 cm的患者2年局部复发率分别为22%和17%。
带有人工胸腔积液和/或腹水的射频消融术对位于肝表面和肝穹窿的肿瘤有效。